Abstract
One of the current challenges in gene therapy is to construct a vector that will target specific tissues. Targeting expression to endothelium is of particular interest in the treatment of several pathologies. We have shown previously that defined regions of the E-selectin and KDR promoters confer endothelial cell specific expression following retroviral delivery. However, the levels of expression were low. In an attempt to increase expression but to preserve the tissue specificity we have examined hypoxic and cytokine-inducible enhancer elements in combination with the KDR and E-selectin promoters. Both enhancers should be active in the tumour environment, boosting expression and giving additional specificity of gene expression in the tumour endothelium. The hypoxia response element (HRE) of the murine phosphoglycerate kinase-1 (PGK-1) promoter was used as a hypoxic enhancer and the tandem-binding site for NFκB from the murine vascular cell adhesion molecule-1 (VCAM-1) promoter as a cytokine-inducible enhancer. The HRE conferred hypoxia inducibility to the KDR and E-selectin promoters. Endothelial specificity of expression was retained with the KDR but not the E-selectin promoter. The NFκB-binding site conferred responsiveness to TNF-α to the KDR promoter, however the level of induction was less than that achieved with the HRE. Retrovirus combining both enhancer elements transferred inducibility by hypoxia and TNF-α, and reached the highest expression levels upon stimulation. These results confirm that heterologous enhancer elements may operate on a single endothelial cell specific promoter. These findings make the use of inducible enhancers a promising strategy for increasing tissue specific gene expression.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Jaggar RT et al. Endothelial cell-specific expression of tumor necrosis factor-a from the KDR or E-selectin promoters following retroviral delivery Hum Gene Ther 1997 8: 2239–2247
Quinn TP et al. Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium Proc Natl Acad Sci USA 1993 90: 7533–7537
Bevilacqua MP et al. Endothelial leukocyte adhesion molecule 1: an inducible receptor for neutrophils related to complement regulatory proteins and lectins Science 1989 243: 1160–1165
Brown LF et al. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer Hum Pathol 1995 26: 86–91
Kraling BM et al. E-selectin is present in proliferating endothelial cells in human hemangiomas Am J Pathol 1996 148: 1181–1191
Fox SB et al. The increased expression of adhesion molecules ICAM-3, E- and P-selectins on breast cancer endothelium J Pathol 1995 177: 369–376
Vaupel PW . Oxygenation of solid tumors. In: BA Teicher (ed.) Drug Resistance in Oncology Marcel Decker: New York 1993 53–85
Wang GL et al. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension Proc Natl Acad Sci USA 1995 92: 5510–5514
Dachs GU et al. Targeting gene expression to hypoxic tumor cells Nature Med 1997 3: 515–520
Maxwell PH et al. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth Proc Natl Acad Sci USA 1997 94: 8104–8109
Maxwell PH et al. The tumour supressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolyses Nature 1999 399: 271–275
Firth JD et al. Oxygen-regulated control elements in the phosphoglycerate kinase 1 and lactate dehydrogenase A genes: similarities with the erythropoietin 3′ enhancer Proc Natl Acad Sci USA 1994 91: 6496–6500
Binley K et al. An adenoviral vector regulated by hypoxia for the treatment of ischaemic disease and cancer Gene Therapy 1999 6: 1721–1727
Collins T et al. Transcriptional regulation of endothelial cell adhesion molecules: NF-kB and cytokine-inducible enhancers FASEB J 1995 9: 899–910
Tian H, Mcknight SL, Russell DW . Endothelial pas domain protein 1 (Epas1), a transcription factor selectively expressed in endothelial cells Gene Dev 1997 11: 72–82
Wiesener MS et al. Induction of endothelial Pas domain protein-1 by hypoxia: characterization and comparison with hypoxia-inducible factor-1alpha Blood 1998 92: 2260–2268
Boyle EMJ et al. Transcriptional arrest of the human E-selectin gene J Surg Res 1999 82: 194–200
Gerber H-P et al. Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes J Biol Chem 1997 272: 23659–23667
Yin LY et al. Genomic structure of the human KDR/flk-1 gene Mamm Genome 1998 9: 408–410
Hata Y et al. Transcription factors Sp1 and Sp3 alter vascular endothelial growth factor receptor expression through a novel recognition sequence J Biol Chem 1998 273: 19294–19303
Kappel A et al. Identification of vascular endothelial growth factor (VEGF) receptor-2 (Flk-1) promoter/enhancer sequences sufficient for angioblast and endothelial cell-specific transcription in transgenic mice Blood 1999 93: 4284–4292
Patterson C et al. Nuclear protein interactions with the human KDR/Flk-1 promoter in vivo. Regulation of Sp1 binding is associated with cell type-specific expression J Biol Chem 1997 272: 8410–8416
Giraudo E et al. Tumor necrosis factor-alpha regulates expression of vascular endothelial growth factor receptor-2 and of its co-receptor neuropilin-1 in human vascular endothelial cells J Biol Chem 1998 273: 22128–22135
Patterson C et al. Down-regulation of vascular endothelial growth factor receptors by tumor necrosis factor-alpha in cultured human vascular endothelial cells J Clin Invest 1996 98: 490–496
Williams RL, Courtneidge SA, Wagner EF . Embryonic lethalities and endothelial tumors in chimeric mice expressing polyoma virus middle T oncogene Cell 1988 52: 121–131
Markowitz D, Goff S, Bank A . Construction and use of a safe and efficient amphotropic packaging cell line Virology 1988 167: 400–406
Pepper MS et al. In vitro angiogenic and proteolytic properties of bovine lymphatic endothelial cells Exp Cell Res 1994 210: 298–305
McCarthy SA, Bicknell R . Responses of pertussis toxin-treated microvascular endothelial cells to transforming growth factor beta 1. No evidence for pertussis-sensitive G-protein involvement in TGF-beta signal transduction J Biol Chem 1992 267: 21617–21622
Morgenstern JP, Land H . Advanced mammalian gene transfer: high titre vectors with multiple drug selection markers and a complementary helper-free packaging cell line Nucleic Acids Res 1990 18: 3587–3596
Yu SF et al. Self-inactivating retroviral vectors designed for transfer of whole genes into mammalian cells Proc Natl Acad Sci USA 1986 83: 3194–3198
Acknowledgements
The authors thank Dr Martin K Oehler of the Angiogenesis Laboratory for helpful discussions, especially concerning statistical analysis of data. This work was funded by the Imperial Cancer Research Fund. CWP thanks the Medical Research Council (UK) for financial support.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Modlich, U., Pugh, C. & Bicknell, R. Increasing endothelial cell specific expression by the use of heterologous hypoxic and cytokine-inducible enhancers. Gene Ther 7, 896–902 (2000). https://doi.org/10.1038/sj.gt.3301177
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.gt.3301177
Keywords
This article is cited by
-
Parkia speciosa empty pod extract exerts anti-inflammatory properties by modulating NFκB and MAPK pathways in cardiomyocytes exposed to tumor necrosis factor-α
Cytotechnology (2019)
-
Therapeutic Improvement of a Stroma-Targeted CRAd by Incorporating Motives Responsive to the Melanoma Microenvironment
Journal of Investigative Dermatology (2013)
-
Enhanced CRAd Activity Using Enhancer Motifs Driven by a Nucleosome Positioning Sequence
Molecular Therapy (2013)
-
Double suicide genes driven by kinase domain insert containing receptor promoter selectively kill human lung cancer cells
Genetic Vaccines and Therapy (2011)
-
Active Adenoviral Vascular Penetration by Targeted Formation of Heterocellular Endothelial–epithelial Syncytia
Molecular Therapy (2011)